Though the MLH1 variant is not considered pathogenetic in the context of Lynch syndrome, we cannot rule out a milder impact contributing to EMS onset, or even a second hit in the endometrial cells, due to the role of the gene MLH1 in endometrial cancer. This evidence concerns the gene MLH1 and endometrial cancer.